AOL Money & Finance

Has Wal-Mart's $4 drug program begun to lose gas?

More

Walgreen (NYSE:WAG) and Rite Aid (NYSERAD) both turned in excellent results for the last quarter. Part of the message sent by both companies is that Wal-Mart Stores, Inc. (NYSE:WMT) $4 generic drug program is not hurting them. But Wal-Mart said its November pharmacy sales were up sharply.

Some part of this does not make sense. Some analysts say that the Wal-Mart drug buyers as consumers without insurance who were not going to any store while the mainstream pharmacies cater to patients who are insured. Rite Aid and its large competitors keep more generic drugs stocked in its stores, and their prices are not very different from Wal-Mart's.

If there is a surge in the purchase of generic drugs that is fueling growth at both Wal-Mart and Walgreen, that would be a problem to Big Pharma companies whose patent drug sales are being eroded by generics already.

Again, that answer would be too simple. Some data still appears to be missing.

While the mystery of both Wal-Mart and Walgreen both doing well is still open, one piece of data does appear to be clear. CostCo took a shot at $4 generics and lost money. They moved the price point to $10.

Lost money? Can Wal-Mart be making any at $4? If not, one of Wal-Mart's biggest initiatives could be a bust.

Douglas A. McIntyre is a partner at 24/7 Wall Street.

Reader Comments (Page 1 of 1)

Symbol Lookup
IndexesChangePrice
DJIA-42.7810,408.17
NASDAQ-11.442,164.57
S&P 500-3.231,103.01

Last updated: November 24, 2009: 12:30 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines